The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy
Abstract
Diabetic neuropathy is one of the most common long‐term complications in patients with diabetes mellitus, with a prevalence of 60–70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief, but they do not affect the underlying pathology nor do they slow progression of the disease. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process. Data from experimental studies indicate that epalrestat reduces sorbitol accumulation in the sciatic nerve, erythrocytes, and ocular tissues in animals, and in erythrocytes in humans. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo. Epalrestat is well tolerated, and the most frequently reported adverse effects include elevations in liver enzyme levels and gastrointestinal‐related events such as nausea and vomiting. Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy. Long‐term, comparative studies in diverse patient populations are needed for clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Pirart, J. (1978) · Diabetes Care · doi:10.2337/diacare.1.3.168 · Cited by 1,290
Vinik, A. I., Park, T. S., Stansberry, K. B., & Pittenger, G. L. (2000) · Diabetologia · doi:10.1007/s001250051477 · Cited by 489
Diabetic Neuropathy: An intensive review
Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R., & Rasmussen, K. A. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.2.160 · Cited by 382
Cited by
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Aldose Reductase, Oxidative Stress, and Diabetic Mellitus
Tang, W. H., Martin, K. A., & Hwa, J. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00087 · Cited by 458
Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications
Guo, M., Sun, X., Chen, J., & Cai, T. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.030 · Cited by 386
Metadata
- Authors
- Ramirez, M. A., & Borja, N. L.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2008-05
- Volume
- 28
- Issue
- 5
- Pages
- 646-655
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2154789716
- Cited by
- 303
- References
- 4
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy. https://app.cochat.ai/papers/10.1592/phco.28.5.646
- The paper
- Ramirez, M. A., & Borja, N. L. (2008). Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.28.5.646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.